Cancer Research Articles

FCS continues to expand the number and scope of clinical trial opportunities available to cancer patients in the community setting.

In a recent evaluation, empirical data indicates FCS decreased emergency room visits not resulting in an admission or observation stay by 18% and decreased inpatient hospital admissions by 15% from 2017 – 2020. 

FCS in partnership with the Leesburg Chamber of Commerce, City of Leesburg and Red Apples Media, is sponsoring a panel discussion with area physicians to provide the latest information about COVID-19.

A survey conducted found that patients overwhelmingly prefer that the FCS physicians, nurses and staff members are vaccinated and wear masks to reduce the spread of COVID-19.

In response to growing concerns amidst the statewide surge of COVID-19 variants, FCS will require all physicians and team members to be fully vaccinated by October 1, 2021.

The in-house oral oncolytic pharmacy of Florida Cancer Specialists & Research Institute (FCS), known as Rx To Go, has been accredited by the National Association of Boards of Pharmacy® (NABP®) for both specialty pharmacy and digital pharmacy practice.

Medical oncologist James Reeves, MD, a member of the Florida Cancer Specialists & Research Institute (FCS) Clinical Research Team, is co-author of an abstract entitled “Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).”

Dr. Hugo Davila, who practices urology and minimally-invasive surgery with Florida Healthcare Specialists (FHS), is the lead author of a new study entitled “Evaluation of the Pubocervical Fascia with 3-Dimensional Endovaginal Ultrasonography (EVUS) and Correlation with Intraoperative Findings during Robotic Sacrocervicopexy.”